Publications by authors named "M S Hofman"
Article Synopsis
- The study aimed to conduct a systematic review and meta-analysis on the adherence of radiomics studies to the Radiomics Quality Score (RQS).
- A total of 130 systematic reviews were analyzed, revealing that while adherence to RQS has improved over time, many studies still struggle to provide high-quality evidence necessary for clinical application.
- Overall, only a small percentage of studies achieved a high RQS, indicating that the quality of radiomics research varies significantly between different imaging modalities.
Objective: To perform a systematic review and meta-analysis to assess the relationship between intraprostatic maximum standardised uptake value (SUV) of the dominant prostatic lesion as measured on preoperative prostate-specific membrane antigen (PSMA) positron emission tomography (PET) with radical prostatectomy International Society of Urological Pathology (ISUP) Grade Group, pathological tumour (pT) staging, and biochemical recurrence (BCR).
Methods: Prostate-specific membrane antigen PET may offer non-invasive assessment of histopathological and oncological outcomes before definitive treatment. SUV of the dominant lesion has been explored as a prognostic biomarker.
Background: Metastatic gastroenteropancreatic neuroendocrine neoplasms (GEPNEN) can cause ectopic Cushing's syndrome (ECS). ECS is highly morbid and medical therapy is complex and can be ineffective. Patients unsuitable for bilateral adrenalectomy (BA) have dismal outcomes.
View Article and Find Full Text PDFArticle Synopsis
- Advances in molecular diagnostics are transforming how prostate, renal, and urothelial cancers are assessed, offering more accurate detection methods for disease burden and minimal residual disease (MRD).
- A literature review from 1980-2024 highlights emerging radiographic and molecular tools aimed at improving disease quantification and monitoring through innovative technologies and biomarker-informed trials.
- New developments, like novel radiotracers and molecular detection methods (e.g., circulating tumor DNA), provide insights into disease mechanisms and have the potential to enhance clinical management, although full MRD application is still in progress.